Despite recent advances in immunotherapies and targeted therapies for patients with advanced melanoma, treatment options are at times limited by the availability of reliable molecular markers, development of drug resistance, and the need for better early diagnosis. An overview of current challenges facing this patient population, as well as an in-depth analysis of treatment modalities, will benefit clinicians in selecting treatment options for patients with melanoma.

These NCCN Guidelines Insights focus on the update to neoadjuvant systemic therapy options and summarize the new clinical data evaluated by the NCCN panel for the recommended therapies in Version 2.2024 of the NCCN Guidelines for Cutaneous Melanoma.

The rapidly evolving treatment landscape for metastatic cutaneous melanoma is reflected in the new update of the NCCN Guidelines for Cutaneous Melanoma. Being familiar with the most current recommendations by the NCCN Panel will help clinicians in their multidisciplinary collaborations and to better support their patients.

The rapidly evolving treatment landscape for metastatic cutaneous melanoma is reflected in the new update of the NCCN Guidelines for Cutaneous Melanoma. Being familiar with the most current recommendations by the NCCN Panel will help clinicians in their multidisciplinary collaborations and to better support their patients.

Pharmacists play a critical role in patient education, monitoring, and management of treatment-related toxicities and will benefit from a comprehensive review of the novel treatments for cutaneous melanoma.

Despite recent advancements in immunotherapies and targeted therapies for melanoma patients with late stage disease, treatment options for these patients are not limited to systemic therapies. An overview of current challenges facing this patient population, as well as an in-depth analysis of treatment modalities, will be beneficial to the oncology care team.

Pharmacists play a critical role in patient education, monitoring, and management of treatment-related toxicities and will benefit from a comprehensive review of the novel treatments for cutaneous melanoma.

This activity will address the increasing use of biomarker testing in the management of patients with melanoma, the factors affecting the selection of the appropriate tests, challenges of interpreting test results and communicating the results to patients, and new developments in biomarker testing.

To try to address the many controversies regarding molecular testing, the NCCN Guidelines for Cutaneous Melanoma now includes a lengthy section on the Principles of Molecular Testing. This covers molecular tests in development that are not yet recommended, and describes recommended tests, the contexts in which they should be employed, and how to use results to inform clinical management. 

Expert review of the data and presentation of different approaches to complex cases would help clinicians appreciate the range of clinical practice across NCCN Member Institutions, and highlight key considerations when presenting patients with options for treatment.